| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:3-(3-(4-Decylphenyl)-1,2,4-oxadiazol-5-yl)propan-1-amine
CAS:2763730-97-6
Purity:99% Package:5mg;10mg;25mg;50mg;100mg;250mg Remarks:BD01560992
|
| Company Name: |
Henan Alpha Chemical Co., Ltd.
|
| Tel: |
0371-55013243 15324716602 |
| Email: |
2853979810@qq.com |
| Products Intro: |
Product Name:3-(3-(4-Decylphenyl)-1,2,4-oxadiazol-5-yl)propan-1-amine
CAS:2763730-97-6
Purity:98% Package:g；kg
|
1,2,4-Oxadiazole-5-propanamine, 3-(4-decylphenyl)- manufacturers
- SLF1081851
-
- $51.00 / 1mg
-
2025-05-01
- CAS:2763730-97-6
- Min. Order:
- Purity: 98.57%
- Supply Ability: 10g
|
| | 1,2,4-Oxadiazole-5-propanamine, 3-(4-decylphenyl)- Basic information |
| | 1,2,4-Oxadiazole-5-propanamine, 3-(4-decylphenyl)- Chemical Properties |
| Boiling point | 481.3±55.0 °C(Predicted) | | density | 1.004±0.06 g/cm3(Predicted) | | pka | 9.33±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | 1,2,4-Oxadiazole-5-propanamine, 3-(4-decylphenyl)- Usage And Synthesis |
| Uses | SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system[1][2]. | | in vivo | SLF1081851 (20 mg/kg; i.p., 4 h postdose) significantly inhibits circulating lymphocytes and plasma S1P, and recapitulates the genetic phenotype of Spns2 null mice[1].
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; blood was drawn 4 h postdose | | Result: | Significantly decreased circulating lymphocyte count and plasma S1P concentration. |
| Animal Model: | SpragueDawley mice (4-week-old)[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose | | Result: | Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0). |
| | References | [1] Russell Fritzemeier, et al. Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors. J Med Chem. 2022 Jun 9;65(11):7656-7681 DOI:10.1021/acs.jmedchem.1c02171 |
| | 1,2,4-Oxadiazole-5-propanamine, 3-(4-decylphenyl)- Preparation Products And Raw materials |
|